Literature DB >> 20963686

[Ultrasound for surveillance after endovascular repair of abdominal aortic aneurysm--simple and safe?].

K Pfister1, S Krammer, M Janotta, E M Jung, P Kasprzak.   

Abstract

In the past, multislice computed tomography angiography (CTA) with arterial and venous phase was recommended as the gold standard in follow-up after endovascular abdominal aneurysm repair (EVAR). Iodine-containing contrast agents and frequent radiation exposure are limitations for use in elderly patients with chronic renal insufficiency. Colour-coded Doppler sonography (CCDS) and, especially, contrast-enhanced ultrasound (CEUS) are non-invasive methods that are time and cost effective. Both provide a reliable alternative to CTA in surveillance after EVAR. CEUS seems to be superior in characterisation of the type of endoleaks and can be established in order to reduce iodine-containing contrast agent and radiation exposure in follow-up. In contrast to CTA scans, CEUS can be offered to patients with chronic renal insufficiency and allows a dynamic examination and perfusion analysis (e. g., in fenestrated and branched stentgrafts). Routine combination with X-ray allows control of stentgraft material and location of the branches. © Georg Thieme Verlag KG Stuttgart ˙ New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20963686     DOI: 10.1055/s-0030-1262548

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  2 in total

1.  Correspondence (letter to the editor): A new approach to early diagnosis?

Authors:  Thomas Bein; Karin Pfister; Piotr Kasprzak; Hans Jürgen Schlitt; Bernhard M Graf; Ernst-Michael Jung
Journal:  Dtsch Arztebl Int       Date:  2012-10-19       Impact factor: 5.594

Review 2.  Diagnostic imaging methods applied in long-term surveillance after EVAR. Will computed tomography angiography be replaced by other methods?

Authors:  Karolina Stefaniak; Michal Stanisic; Marcin Gabriel; Grzegorz Oszkinis
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-02-11       Impact factor: 1.426

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.